Jonathon Sedgwick PhD

Dr. Jonathon Sedgwick born in Perth Australia is an Immunologist, educated at the University of Western Australia with post-doctoral education at the University of Oxford UK with Don Mason, Neil Barclay, and Alan Williams. His subsequent career included ten years in academic research at the University of Wurzburg Germany, and the Centenary Institute of Cancer Medicine, Sydney Australia, six years as Group Director, Immunology, at the DNAX Research Institute, Schering Plough/Merck’s biotech arm in Palo Alto, California, and 11 years with Eli Lilly and Company where he held a number of roles including Chief Scientific Officer, Cancer Inflammation Research; Managing Director and Chief Scientific Officer of Lilly’s Singapore Research Center, and Chief Scientific Officer, Autoimmunity Discovery Research and Distinguished Research Fellow, Biotechnology and Autoimmunity.

In November 2015 Jonathon joined BI as Vice President and Global Head Immune Modulation and Biotherapeutics Discovery Research. In December 2016 Jonathon was appointed to the new role of Vice President and Global Head Cancer Immunology and Immune Modulation responsible for the development of the Immuno-oncology discovery and early clinical portfolio, and for immune-modulation research globally covering all therapy areas.